Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis

References

• Al Hajjar S, McIntosh K. The first influenza pandemic of the 21st century. Ann Saudi Med 2010;30:1–10.
   PubMed Web of Science ®Google Scholar
• Kumar S, Havens PL, Chusid MJ, Willoughby RE Jr, Simpson P, Henrickson KJ. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. Pediatr Infect Dis J 2010;29:591–4.
   PubMed Web of Science ®Google Scholar
• Schout D, Hajjar LA, Galas FR, Uip DE, Levin AS, Caiaffa Filho HH, . Epidemiology of human infection with the novel virus influenza A (H1N1) in the Hospital das Clínicas, São Paulo, Brazil, June–September 2009. Clinics (Sao Paulo) 2009;64: 1025–30.
   PubMed Web of Science ®Google Scholar
• Faco MM, Leone C, Campos LM, Febrônio MV, Marques HH, Silva CA. Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus. Braz J Med Biol Res 2007;40:993–1002.
   PubMed Web of Science ®Google Scholar
• Barash J, Goldzweig O. Possible role of streptococcal infection in flares of juvenile idiopathic arthritis. Arthritis Rheum 2007; 57:877–80.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Update: influenza activity – United States, August 30, 2009–January 9, 2010. MMWR Morb Mortal Wkly Rep 2010;59:38–43.
   PubMedGoogle Scholar
• Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, . Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1–62. (Erratum, MMWR Recomm Rep 2010;59:1147. MMWR Recomm Rep 2010;59:993)
   PubMedGoogle Scholar
• Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, . EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704–12.
   PubMed Web of Science ®Google Scholar
• EMA. Committee for Proprietary Medicinal Products (CPMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products, 2004. Available from: http://archives.who.int/prioritymeds/report/append/62EMEAguidelines.pdf.
   Google Scholar
• EMA. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. London: European Medicines Agency, 1996. (Publication no. CPMP/BWP/214/96). Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003945.pdf.
   Google Scholar
• USFDA. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf.
   Google Scholar
• Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001;19:589–94.
   PubMed Web of Science ®Google Scholar
• Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011;30:208–11.
   PubMed Web of Science ®Google Scholar
• Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993;20:1769–73.
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, . Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012;39:167–73.
   PubMed Web of Science ®Google Scholar
• Petty RR, Southwood T, Manners P, Baum J, Glass DN, Goldenberg J, . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 2:390–2.
   Google Scholar
• Kendal AP, Pereira MS, Skehel JJ, editors. Concepts and procedures from laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention, 1982.
   Google Scholar
• Food and Drug Administration Center for Biologics Evaluation and Research Office of Vaccines Research and Review. Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines, 2009. Available from: www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/BloodVaccinesandOther Biologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ UCM172424.pdf.
   Google Scholar
• Machado CS, Ruperto N, Silva CH, Ferriani VP, Roscoe I, Campos LM, . Paediatric Rheumatology International Trials Organisation. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S25–9.
   Google Scholar
• Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, . Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010;28:5857–63.
   PubMed Web of Science ®Google Scholar
• Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, . Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56–66.
   PubMed Web of Science ®Google Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138–49.
   PubMed Web of Science ®Google Scholar
• Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, . Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011;70: 2144–7.
   PubMed Web of Science ®Google Scholar
• Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011;6:e16496.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, . The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010;39:442–7.
   PubMed Web of Science ®Google Scholar
• Borba EF, Saad CG, Pasoto SG, Calich ALG, Aikawa NE, Ribeiro ACM, . Antimalarials: a window of opportunity to improve the influenza A/H1N1 vaccine response in lupus patients under immunosuppressive agents. Arthritis Rheum 2011;63(Suppl 10):581.
   Google Scholar
• Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB, . Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011;63:3502–11.
   PubMed Web of Science ®Google Scholar
• Kasapçopur O, Cullu F, Kamburoğlu-Goksel A, Cam H, Akdenizli E, Calýkan S, . Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128–30.
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, . Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:1384–7.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Agmon-Levin N. ‘Asia’ – autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36:4–8.
   PubMed Web of Science ®Google Scholar